Haemonetics Corporation

HAE Healthcare Medical Devices

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

118.28 3.01 −2.48%
Market cap
$5.5B
P/E
57.7×
Fwd P/E
18.0×
Dividend yield
—
F-score
6/9
Altman Z
2.21
Beneish M
−2.81
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

14.17 21.96 27.76 36.59
P/S ratio
1.75 2.84 1.99 2.52
P/FCF ratio
8.95 12.04 10.16 11.63
P/Operating CF
20.84 40.08 37.48 65.02
P/B ratio
2.73 4.11 3.34 4.06
EV/Sales
2.22 3.27 2.72 3.22
EV/EBITDA
8.01 11.57 13.25 15.88
EV/FCF
11.36 13.83 13.88 14.86
Current Ratio
1.64 1.75 2.95 3.08
Net Debt/EBITDA
7.03 5.79 226.86 11.18
Debt/Equity
1.08 1.01 1.53 1.40
Earnings Yield
7.06% 4.55% 3.60% 2.73%
Free Cash Flow Yield
11.17% 8.30% 9.85% 8.60%
Free Cash Flow per Share
2.24 1.87 1.14 0.98
Book value per Share
17.84 19.48 16.88 18.45
Free Cash Flow
106.43 87.65 53.81 44.65
EV/EBIT
12.13 17.15 23.18 27.12
Other line items

Show all line items

Columns are period end dates